We and others have shown that members of the Ets family of transcription factors are involved in morphogenic properties of endothelial cells in vitro. To investigate the role of these factors in the transcriptional regulation of angiogenesis in vivo, we set up a nontraumatic model that allows daily macroscopic examination of both growth factor-and tumor-induced angiogenesis in mouse ears. In the same animal, we were thus able to record variations in the patterns of neovessels induced and cell populations recruited by the angiogenic factors FGF-2 and VEGF. In this model, inhibition of FGF-2-induced angiogenesis by the pharmacological compound TNP-470 was readily observed, demonstrating that the mouse ear model is also useful in the evaluation of antiangiogenic strategies. Our functional analysis of Ets transcription factors activity utilized a competitor protein, Ets1-DB, a dominant negative Ets1 mutant lacking the transactivation domain. Retrovirus-mediated expression of Ets1-DB inhibited FGF-2-induced angiogenesis, while the expression of Ets1-DB in cancerous and stromal cells disturbed tumorinduced angiogenesis. These results illustrate the value of the ear model and highlight the role of Ets family members in the transcriptional regulation of tumor angiogenesis.
Introduction
The formation of new blood vessels (neovessels) is essential to normal and pathological development. Understanding the transcriptional mechanisms that control the activation of endothelial cells and the development of neovessels should point out new therapeutic targets and provide useful informations for targeting gene expression in blood vessels. Compared to the understanding of the ontogeny of muscles, the eye or the hematopoietic system, little is known about the transcriptional control of blood vessel development.
Ets1 is the founder of a growing family of transcription factors comprising over 50 members characterized by a conserved DNA-binding domain (Sharrocks et al., 1997; Laudet et al., 1999) . The expression of Ets1 is associated with the activation of endothelial cells during blood vessel formation in the embryo (reviewed in Lelievre et al., 2001 ). Ets1 expression is no longer detected in quiescent endothelial cells of large blood vessels or adult capillaries, but this expression is induced during healing (Wernert et al., 1992; Ito et al., 1998; Tanaka et al., 1998) and pathological processes such as tumor development (Wernert et al., 1994) . Ets1 transcripts also accumulate in the fibroblastic stroma surrounding invasive tumors (Wernert et al., 1994; Bolon et al., 1995 Bolon et al., , 1996 . Altogether, Ets1 expression generally correlates with the occurrence of invasive processes during normal and pathological development (Delannoy Courdent et al., 1996; Fafeur et al., 1997) .
Although an important perinatal lethality has been described in mice homozygous for a null mutation of the Ets1 gene, no perturbation of the endothelial network structure or function in these mice has been reported so far. This suggests that Ets1 is not strictly necessary for embryonic development or for blood vessel formation (Barton et al., 1998) . Other Ets family members such as Erg, Fli1 and Tel are coexpressed with Ets1 in endothelial cells (Dhordain et al., 1995; Edel, 1998; Macias et al., 1998; Mager et al., 1998) . Since Ets proteins display overlapping DNA-binding specificities in vitro, a degree of redundancy could account for the nonlethal phenotype in Ets1 null mice.
The role of Ets1 during angiogenesis has been assessed by in vitro studies. Ets1 expression is induced upon stimulation by angiogenic factors such as FGF-1, FGF-2, VEGF and EGF of proliferating and migrating endothelial cells, and is switched off as cells reach confluence (Tanaka et al., 1998; Wernert et al., 1992) .
The latter observation can be compared to the loss of Ets1 expression in endothelial cells of adult tissues (Wernert et al., 1992) . In vitro promoter studies and/or cotransfection experiments have shown that Ets factors can transactivate the promoters of a range of genes encoding endothelial cell markers or proteins associated with angiogenic processes, namely growth factor receptors or adhesion molecules (Schwachtgen et al., 1997; Iljin et al., 1999) . Ets factors have also been shown to interact or cooperate with other transcription factors in the activation of the promoters of genes encoding extracellular matrix proteases or their inhibitors Wasylyk et al., 1991; Logan et al., 1996) . Interstitial collagenase (MMP-1) is expressed in activated endothelial cells in vitro as well as in stromal fibroblasts of invading tumors. In endothelial cells, Ets1 antisense oligonucleotides inhibit the expression of MMP-1 and urokinase-type plasminogen activator (uPA) induced by angiogenic factors and reduce tube formation and invasion capabilities (Iwasaka et al., 1996) . By contrast, Ets1 overexpression promotes endothelial cell invasiveness and expression of matrix proteases as well as integrin b3, conferring an angiogenic phenotype to these cells (Oda et al., 1999) . Taken together, these results point to Ets1 as a coordinator of the various functions characterizing activated endothelial cells, including the secretion of matrix-degrading enzymes and the concomitant modulation of the expression of a group of membranebound integrins and cell-to-cell adhesion molecules.
Based on these findings, the manipulation of Ets1 expression or activity during tumor angiogenesis could be considered as a therapeutic approach. In previous studies, the inhibition of Ets transcriptional activity was achieved by using an Ets1 mutant (Ets1-DB) lacking its transactivation domain, designed to compete for DNA binding with Ets1 and possibly other members of the Ets family. Stable expression of Ets1-DB was achieved in murine brain capillary endothelial cells after infection with an ecotropic MFG retroviral vector (MFG-Ets1-DB-Ires-Neo R ). These cells showed increased spreading and adhesion and a higher capacity to form branched structures in a Matrigel R matrix . While overexpression of wild-type Ets1 in endothelial cells induced the expression of VE-cadherin and a decrease in cell density at confluence, the Ets1-DB mutant reduced the expression of endogenous VEcadherin (Lelievre et al., 2000) . Different results were obtained with a similar transdominant negative mutant of Ets1 (TMEts1) delivered by adenoviral infection (Nakano et al., 2000) . This mutant was shown to impair the migration and invasive properties of endothelial cells, and to reduce their ability to form capillary-like tubes in Matrigel R . It is known that capillary morphogenesis involves an intricate interplay between extracellular matrix degradation and neosynthesis, cell-to-cell and cell-to-extracellular matrix adhesion. It is very likely that the discrepancies between the in vitro effects of our retrovirus-encoded mutant Ets1-DB and the adenovirus-encoded TMEts1 can be accounted for by slight differences in the design and expression levels of the mutants and in the cell lines used (murine brain capillary endothelial cells versus endothelial cells derived from the spleen of newborn mice). In addition, endothelial cell invasion was inhibited in subcutaneously injected Matrigel R plugs loaded with FGF-2 and the adenovirus encoding TMEts-1 (Nakano et al., 2000) .
In this study, we used the MFG Ets1-DB retroviral vector to study the role of Ets factors in both normal and tumor angiogenesis. Since in vitro experiments with this vector suggested that Ets factors are involved in the morphogenic properties of activated endothelial cells, we sought a valid in vivo model that would enable us to document the morphogenesis of the neovasculature. We developed a nontraumatic model in the mouse ear that allowed us to monitor in the same living animal (both macroscopically and by intravital fluorescence microscopy) the induction of angiogenesis by FGF-2 and VEGF, and the inhibitory effect of the pharmacological agent TNP-470 on FGF-2-induced local angiogenesis. We then investigated whether intravenously injected retroviruses encoding Ets1-DB could infect activated endothelial cells and interfere with FGF-2-induced angiogenesis. This mouse ear model was also useful in the study of the angiogenic activity of tumors, and we investigated in parallel the effects of Ets1-DB expression on tumor vessel formation.
Results
The mouse ear model readily displays differences between the angiogenic effects of FGF-2 and VEGF Since in vitro studies had suggested that Ets factors are involved in the morphogenic properties of endothelial cells, we set out to develop a model addressing Ets function in vivo. We optimized a nontraumatic model in the mouse pinnae that allows daily macroscopic examination of vascular tree morphogenesis in a living animal, in response to angiogenic stimuli. A sponge loaded with angiogenic factors was inserted near the margin of the ear, in between and beneath existing vessels. In this work, over 200 bilaterally grafted mice altogether were used in different protocols. Each experiment recording the angiogenic effects of VEGF and FGF-2, for doses ranging from 100-1000 ng, was carried out five times. Every experiment involved 8-24 mice, with 3-6 sponge implants used at each dose point. Solvent-alone control implants were always negative for macroscopically detectable angiogenic development during the time span of the experiments (Figure 1a) . Dose-dependent angiogenic responses could be recorded for both FGF-2 (Figure 1b-c) and VEGF ( Figure 1d and data not shown). FGF-2 induced the growth of numerous large vessels that eventually surrounded the implant area completely. Of particular interest was the persistence of these neovessels for 3 weeks in the immediate vicinity of the sponge implant, contrary to the regression of neovessels located below the implant area, where the implantation canal had been opened. FGF-2 angiogenic response was also edematous, characterized by a colored dose-dependent inflamed aspect of the implantation area. This inflammatory response was detected with FGF-2 from different origins (R&D and Sigma #0291) in doses as low as 10 ng (data not shown), and regressed after 1-2 weeks depending on the dose. It was completely abolished by prior boiling of FGF-2, indicating that it was specific for this factor, and not due to a heatresistant contaminant (data not shown).
Neovessels induced by VEGF formed loops that later regressed or reorganized around the implant (Figure 1d ). Although VEGF is also known as the vascular permeability factor, it induced a much more discrete permeation of vascular fluids than FGF-2 at the macroscopical level.
Histological analyses after May-Gru¨nwald-Giemsa or hematoxylin/eosin staining confirmed that vessel invasion in growth factor-loaded sponges was dosedependent and occurred faster postimplantation (as Figure 1 Dose-and time-dependent angiogenic responses in the mouse ear model. Solvent-, FGF-2-and VEGF-loaded sponges were implanted in the pinnae of a nude mouse. Blood vessel development around the implants was recorded for 11 days using a stereomicroscope and transillumination. a-d: pairs of representative views of the implant area from the same experiment. Typical views from animals among the same protocol are depicted. Solvent-loaded sponges showed no angiogenic induction (panel a). Note the location of the sponge in between and beneath pre-existing vessels. By contrast, 100 and 500 ng of FGF-2 (b, c, respectively) induced a dose-dependent macroscopic vessel development and an inflamed aspect. The inflammatory response to 500 ng VEGF was lower than that induced by FGF-2 (d). Scale bar: 1 mm Ets factors in normal and tumor angiogenesis A Pourtier-Manzanedo et al early as the end of the first week) for FGF-2 than for VEGF. The diameter of existing vessels increased and numerous neovessels were induced in the periphery of the FGF-2-loaded sponge implants. Vessel density was high and most vessel walls were immature with important interstitial red blood cell leakage. At 2 weeks after implantation, perfused vessels were detectable within FGF-2-loaded sponges in addition to immature and open vascular structures. Within VEGF-loaded implants, invasion was moderate at that time point, neovessels displayed lower permeability (Figures 2a and  b) and fewer perfused neovessels were observed around and within the implants relative to FGF-2 ( Figure 2c ). The examination of infiltrating tissue within FGF-2-loaded implants revealed the presence of mast cells neighboring endothelial cells or neovessels, which were not observed in VEGF-loaded implants (inset in Figure  2b and c). After 3 weeks of FGF-2 or VEGF induction, the entire sponge was filled with granulomatous tissue and vessels.
Differences between the architecture of vascular networks, respectively, induced by FGF-2 and VEGF within the sponge implant could also be recorded in living animals. Mice bearing an FGF-2-loaded implant in one ear and a VEGF-loaded implant in the other ear were given a systemic injection of FITC-dextran and submitted to intravital fluorescence microscopy. With both growth factors, and especially with FGF-2, early angiogenesis was difficult to record 7 days postimplantation due to vessel permeation. After 1 week, new vessels were readily visualized in the same animal, suggesting that they were more mature (data not shown). Reconstruction of confocal optical sections taken from the same representative animal showed that FGF-2-induced neovessels were nonhomogenous in diameter and organized as an anastomotic, tortuous network. The VEGF-induced vessels in the other ear, on the contrary, displayed a more regular architecture and orientation ( Figure 2d ). Confocal microscopy showed that perfusion was more heterogeneous in FGF-2-induced neovessels than in those induced by VEGF.
The mouse ear model allows the evaluation of the inhibitory effects of TNP-470 on FGF-2 responses
To establish whether the mouse ear model could be used to test antiangiogenic strategies, we investigated the ability of the pharmacological angiogenesis inhibitor, TNP-470, to alter the development of FGF-2-induced blood vessels. Animals previously implanted with buffer-or FGF-2-loaded sponges received subcutaneous injections of the pharmacological angiogenesis inhibitor TNP-470 or its solvent (gum arabic in PBS) every 2 days. No angiogenic development was recorded for sponge implants loaded with buffer alone (Figure 3a , d). Treatment with TNP-470 solvent alone had no effect on the induction of vessel development and inflammation by FGF-2 (Figure 3b and e). Animals receiving recurrent TNP-470 injections, on the contrary, displayed a striking reduction in the responses to 100 and 250 ng of FGF-2. Response inhibition was moderate for 500 ng FGF-2 (data not shown). Interestingly, both the number of induced vessels and apparent inflammation were diminished upon macroscopic examination (compare Figure 3b and c). Histological analysis showed that perfused vessels and granulomatous tissue were absent within the sponge implant from TNP-470-treated animals (compare Figure 3e and f).
Reduction in FGF-2-induced angiogenesis by intravenous injections of Ets1-DB-encoding retrovirus
The above results validated our mouse ear model as a tool for the study of both the activation and the inhibition of angiogenesis. We were thus able to use this model in conjunction with the MFG-Ets1-DB-Ires-Neo R retrovirus to investigate the role of Ets factors in angiogenic processes.
In a first series of experiments, we evaluated different protocols for their efficiency in achieving a retroviral infection at the angiogenic site in mice ears. MFG-LacZ, 1-3 Â 10 7 i.p. were administered three times with 2-day intervals by intravenous injections in the tail vein of mice implanted with FGF-2 in one ear and with solvent alone as a control in the opposite ear. An in toto b-galactosidase assay after killing showed a marked blue area overlapping with the area of FGF-2-induced angiogenic response. By comparison, discrete blue spots were restricted to the incision scar in the control ear, probably associated with healing-induced processes. These results showed that cells activated by FGF-2-had been infected by the retroviral vector (Figure 4a ).
In total, 18 mice previously implanted with solventand FGF-2-loaded sponges in either ear received injection courses as above with MFG-Ets1-DB-IresNeo R or MFG-Ires-Neo R retroviral concentrated supernatants. In the absence of FGF-2, neovessel development was absent upon macroscopic examination regardless of retroviral administration (Figure 4b and d) and implantation areas were indistinguishable from those of noninfected animals (not shown). Administration of control MFG-Ires-Neo R retroviruses did not alter the macroscopic angiogenic effects of FGF-2 in this model. By contrast, administration of Ets1-DBencoding retroviruses induced a spectacular reduction in both the inflammatory and angiogenic phenotypes of FGF-2-loaded implants in eight out of 12 implantation areas (compare Figure 4e and c) and a moderate but distinct reduction in the remaining areas.
Retroviral infection of newly formed blood vessels was confirmed by in situ hybridization analysis on histological sections from ears implanted with FGF-2-loaded sponges. Indeed, the endothelial walls of small vessels surrounding the implant showed the presence of neo-gene transcripts whereas larger, presumably preexistent vessels did not (Figure 4f ). These experiments indicated that retroviral infection leading to the expression of a dominant-negative mutant of Ets1 during angiogenesis in vivo had an inhibitory effect on the induced angiogenic process. Histological examination of the same ears after May-Gru¨nwald staining at day 11 (scale bar: 100 mm) showed granulomatous infiltration and angiogenesis (arrows) in the implants (e). TNP-470 treatment induced a dramatic reduction in both the macroscopic and histological angiogenic effects of FGF-2 (f) Figure 4 Reduction of FGF-2-induced angiogenesis by expression of a transdominant negative mutant of Ets1. Animals bearing implants loaded with a 750 ng FGF-2-loaded sponge in one ear and solvent in the other one received three injections in the tail vein on days 0, 1 and 4 postimplantation of 1.5-3 Â 10 7 i.p. of retroviral b-galactosidase expression vector MFG-LacZ. Robust angiogenesis was observed in FGF-2-treated ears. Animals were killed at day 11 and b-galactosidase activity was assayed by X-Gal staining of whole ears (a). The entire angiogenic area surrounding the sponge implant stained blue, indicating retroviral infection of neovessels (a, right ear, white arrowhead). b-galactosidase staining in the control ear was limited to discrete spots associated with reparative angiogenesis along the implantation canal (a, left ear, black arrowhead). Animals were then implanted with 500 ng FGF-2-loaded sponges in one ear (c and e) and solvent in the other one (b and d). Animals received intravenous injections of 1-4 Â 10 7 control MFG-Ires-Neo R (a, c) or MFG-Ets1DB-Ires-Neo R i.p. (d and e) at days 1 and 3 after implantation. Macroscopic examination at day 9 showed no difference and no angiogenic development for ears implanted with solvent and injected with either type of retroviruses (scale bar: 1 mm). By contrast, mice injected with MFG-Ets1-DB-Ires-Neo R retroviruses exhibited a strong reduction in angiogenic development at the site of FGF-2-loaded sponge implantation (e) compared to those injected with control retroviruses (c). In situ hybridization using the neomycin resistance gene as a probe showed that endothelial cells of neovessels surrounding the sponge implant (denoted by a dashed line) had been infected (scale bar: 50 mm). The hybridization signal was evidenced with bright field illumination (f, right). On the same section where only the staining of nuclei by Hoechst 33 258 is observed, the arrowheads point to endothelial cells lining a single vessel (f, left) 
Discussion

Description of growth factor-induced angiogenesis and its inhibition in the ear model
The implantation of growth factor-loaded polyvinyl sponges in mouse pinnae permits a daily macroscopic examination of growth factor-and tumor-induced angiogenesis. Using noninvasive macroscopic techniques, we were able to make continuous, long-term observations of vessel development and remodeling and perform dose-dependent studies of the angiogenic responses to VEGF or FGF-2.
As shown in Figures 1 and 2 , macroscopic observation and histological analysis discriminated the respective angiogenic effects of FGF-2 and VEGF. Within 3 days, FGF-2 induced neovessel recruitment and an increase in the permeability of small pre-existing vessels in the implantation area. Neovessels further developed in a dose-dependent manner. VEGF effects were delayed and more discrete, with a small increase in vascular permeability. In addition, we were able to image by intravital staining the architecture of the growth factorinduced vascular networks. The vascular network Ets factors in normal and tumor angiogenesis A Pourtier-Manzanedo et al induced by FGF-2 was more convoluted and irregular in size than that induced by VEGF. These features are in agreement with recent studies showing that FGF-2 released by adenocarcinoma cells transfected with FGF-2 cDNA induced a microvasculature characterized by a wider average vascular diameter and an extreme variability in the diameter of individual vessels in a nude mice model (Konerding et al., 1998) . The differences between the VEGF and FGF-2 responses were not related to differences between the release of these factors from the hydron-coated polyvinyl sponges, since similar VEGF-and FGF-2-loaded sponges in the culture medium of bovine aortic endothelial cells promoted cell proliferation as efficiently as VEGF or FGF-2 directly added to the medium (A Pourtier-Manzanedo and C Vercamer, data not shown). It has been previously shown in other models that VEGF and FGF-2 induce different responses depending on the site of the assay. Indeed, the number of newly formed vessels and their functional properties such as permeability were different in a dorsal skin chamber relative to an intracranial window; in this intracranial window, FGF-2-induced vessels exhibited an approximately twofold higher permeability than VEGF-induced vessels (Dellian et al., 1996) . In addition, FGF-2 was recently found to be more efficient than VEGF in inducing neovessel development and reducing necrosis in a skin flap ischemia model (Rinsch et al., 2001) . These results suggest that microenvironment specificities may determine, in part, the differences observed between the responses to VEGF and FGF-2 in the ear.
In our studies, VEGF elicited moderate inflammatory effects at the macroscopic and histological levels compared to FGF-2. This could be related to the specific microenvironment of the ear, which is mostly composed of skin and cartilage with thin layers of hypoderm. In histological sections of untreated ear skin, numerous mast cells were observed near the small vessels of the dermis and hypodermis (data not shown). This cellular environment would be more sensitive to FGF-2 than to VEGF. Indeed, FGF-2 displays pleiotropic stimulatory activities on the different cell types present in the ear. It could contribute to inflammation development. FGF-2-loaded sponges showed marked invasion by granulomatous and vascularized tissue with vessel-associated mast cells. Although filled with remodeling tissue, VEGF-loaded sponges did not contain mast cells after 3 weeks. Mast cells contribute to wound healing and angiogenesis by producing proinflammatory and growth-promoting mediators, among which are FGF-2 and VEGF (Artuc et al., 1999) . They also express proteases recently shown to be critical for skin tumor angiogenesis (Coussens et al., 1999) . The ear skin microenvironment, where the sponges are implanted, could therefore be responsible for the important inflammatory effects of FGF-2.
In agreement with the literature, TNP-470 displayed a general inhibitory effect in the ear model, not restricted to endothelial cell proliferation. Indeed, it led to a strong reduction in both the angiogenic and inflammatory effects of FGF-2. Histological analysis revealed inhibition of neovessel and granulomatous tissue invasion in the sponge implant. TNP-470 has been originally shown to be a selective inhibitor of endothelial cells (Maier et al., 1997) until it was also described as a potent inhibitor of fibroblast proliferation (Kria et al., 1998) . TNP-470 also interacts with low-affinity FGF-2 receptors on NIH/3T3 fibroblasts (Bond et al., 2000) . This interaction could also account for the reduced invasion of the sponge implants by granulomatous tissue and presumably neovessels.
Different in vivo assays have already been used to monitor or quantify angiogenesis (Jain et al., 1997) . They aim to combine reduced traumatism for the animal, easy and low-cost experimentation and longterm observation in the living animal. A model has been recently developed which consists in implanting a growth factor-loaded cellulose sponge on a subcutaneous air pocket in the rat (Lichtenberg et al., 1997) . This method is more painful for the animal and does not allow any macroscopic measurement of the angiogenic response. Our model is particularly weakly traumatic for the animal with no false positive. This ear model could be useful for investigating the mechanisms of blood vessel formation and regression in transgenic mice.
Involvement of Ets transcription factors in FGF-2-and tumor-induced angiogenesis
Since Ets1, and other Ets family members such as Erg and Fli, can be expressed in endothelial cells during angiogenesis, they could play redundant roles. We then managed to inhibit their activities by using Ets1-DB, a dominant-negative mutant that could compete with each of these transcription factors . Intravenous injections of MFG-LacZ retroviruses to mice bearing a FGF-2-loaded sponge in one ear and a solvent-loaded sponge in the other ear revealed a conspicuous infection at the angiogenic site and the absence of infection at the control site. The higher rate of proliferation of endothelial and bystander cells at this angiogenic site compared to that at the control site probably accounts for this difference.
Repetitive injections of retroviruses encoding Ets1-DB dramatically reduced both FGF-2 macroscopic effects in this model, that is, the inflammatory and angiogenic responses, whereas injections of control retroviruses had no effects. In situ hybridization using a neo-gene probe, specific for retroviral transcripts, showed that this reduction correlated with the infection of endothelial cells in small neovessels at the periphery of the implant. Few nonendothelial cells were infected by retroviruses encoding Ets1-DB at the vicinity of the angiogenesis site. The numerous neovessels induced at the periphery of the angiogenic implant, when the animals received injections of the control retrovirus, were also infected (data not shown). Due to the mode of administration of these retroviruses, activated circulating vascular cells were massively infected. Retroviral infection was also important in the bone marrow as detected by in situ hybridization (data not shown). Therefore, only a low percentage of injected retroviral particles was able to reach the ear. These i.p. infected angiogenic, proliferating endothelial cells but it is likely that they were not numerous enough to access the stromal compartment.
In the mouse ear model, FGF-2-induced angiogenesis was inhibited upon expression of Ets1-DB. By contrast, the expression of Ets1-DB delivered from the same retroviruses promoted the formation of branched structures in Matrigel R . Endothelial cells in these experimental settings are in different states and environments, and this may account for the differences observed between the effects of Ets1-DB. The differences may also indicate that Ets factors have different effects in FGF-2-dependent and independent angiogenesis. Along these lines, it has been shown that the expression of the DNA-binding domain of Ets2 increases the basal invasion of breast carcinoma cells in Matrigel R and suppresses their CSF-1-enhanced invasive ability (Sapi et al., 1998) . Finally, the role of circulating proinflammatory cells in the promotion of FGF-2-mediated angiogenesis should also be considered. Indeed, several Ets factors are expressed in cells of the immune system (Anderson et al., 1999) . Since members of the Ets family present homologies in their DNAbinding domain, we cannot exclude that the competition of Ets1-DB with Ets factors responsible for the activation of these proinflammatory cells recruited by FGF-2 contributes to the strong reduction in the FGF-2 angiogenic phenotypes recorded in the ear model.
Since Ets1-DB delivered by retroviral infection was efficient to reduce FGF-2-induced angiogenesis in the ear model, we next evaluated the effects of Ets1-DB on tumor development and angiogenesis. Preliminary studies showed that MFG-Ets1-DB-Ires-Neo R -or control virus-producing GP+E86 cells exhibit the same growth characteristics in vitro and induce tumors of equivalent size when subcutaneously implanted in the flank of immunodeficient scid mice. By in situ hybridization with a neo-gene probe, we detected a much lower signal in tumors 3 weeks after injection than 1 week after injection. This suggested a decrease in the efficiency of viral transcript expression with time (data not shown). Reduction in retroviral expression efficiency has already been observed with various murine retroviral vectors (McLachlin et al., 1993; Xu et al., 1989) . Hot spots for the recombination in the genome of MoMuLV vectors could also be responsible for this loss of expression through random integrations (M Lopez-Lastra and JL Darlix, personal communication) .
The mouse ear model allowed us to continuously monitor tumor growth, angiogenesis and vessel recruitment. In addition, contrary to subcutaneous tumors, ear tumors were almost nonnecrotic after 25 days. This is probably due to the fact that cancer cells implanted in the ear recruit new vessels more efficiently. Both tumor types developed and in situ hybridization at day 25 revealed the expression of retroviral transcripts in cancer cells and in tumor vascular network . Although their initial development was slower than the controls, MFGEts1-DB-Ires-Neo R -producing tumors developed and reached similar volumes at day 25. One cannot exclude that retroviral expression became less efficient 3 weeks postimplantation. Consequently, examination of the tumors at early stages could have pointed out stronger differences.
The detection of the endothelium marker CD31/ PECAM revealed that tumors expressing Ets1-DB displayed reduced vessel density at their periphery, reduced vessel lumen diameters and modified architecture of the microvasculature. Various mechanisms may account for these changes. Our in vitro studies suggest a direct effect of Ets1-DB on the morphogenic properties of endothelial cells. Indeed, the expression of Ets1-DB in murine brain capillary endothelial cells increases their adhesion to the extracellular matrix and decreases the expression of VE-cadherin (Lelievre et al., 2000) . We suggest that the same events take place in vivo and favor the formation of smaller vessels. However, the formation of the tumor vasculature is part of the stroma reaction that is determined by the cancer cells themselves and their immediate environment. Beside endothelial cells in tumor-induced neovessels, Ets1 and family members are also expressed in stromal fibroblasts of invasive tumors, in inflammatory cells, as well as in cancer cells (Behrens et al., 2001a, b) . Therefore in these studies, both tumor components can be affected by Ets1-DB in different ways. Further experiments with human cancer cells and murine ecotropic MFG retroviruses will allow one to determine the respective contribution of the stroma and of the cancer cells in the vasculature changes described in these studies.
Materials and methods
Culture of retrovirus-producing cells
The establishment of MFG-Ets1-DB-Ires-Neo R -or MFG-IresNeo R -producing GP + E86 cells has been described previously . Briefly, the cDNA sequence encoding Ets1-DB (the DNA-binding domain of mouse Ets1, amino acids 306-423.) was cloned upstream of the internal ribosome entry site (IRES) and neomycin-resistance gene excised from the pCITE vector and inserted into a retroviral MFG vector in replacement of the Gag, Pol and Env genes. The same construct without the Ets1-DB sequences was used as a control. Virus packaging murine fibroblasts (GP + E86 (Markowitz et al., 1988) ), kindly provided by Dr JL Darlix (Ecole Normale Superieure, Lyon), were then transfected with either MFG plasmid . The MFG-Ets1-DB-IresNeo R -or MFG-Ires-Neo R -producing GP + E86 cells were routinely cultured in tissue culture plastic dishes at 371C in a 95% air, 5% CO 2 humidified atmosphere, in Dulbecco's modified Eagle medium (DMEM), containing 10% heatinactivated calf serum (Hyclone), 8 mg/ml gentamycin, 50 U/ ml penicillin and 50 mg/ml streptomycin.
Animals
Female nu/nu BALB/c mice (IFFA CREDO, L'Arbresle, France), 6-9 weeks old, were housed in a sterile atmosphere in isolators with food and water ad libitum. Surgical procedures were performed in vertical laminar flow hoods under anesthesia, in accordance with the current regulations of the Ministe`re de l'Agriculture, France.
Preparation of growth factor-loaded polyvinyl sponges
Polyvinyl sponge matrix sheets (Rippey Corporation, El Dorado Hills, CA, USA) at 1 mm thickness were kindly provided by Dr Robert Auerbach. Standard 1-mm 3 pieces were cut out and sterilized by gamma-irradiation at 25 Gy. Stock solutions of VEGF (164 amino acids, R&D, # 493-MV-025) and FGF-2 (146 amino acids, R&D, # 233-fb-025) were prepared according to the manufacturer's instructions and diluted in PBS, 0.1% BSA.
Sponge pieces were pinned on the tip of a 26-G needle and loaded with the required dose of the relevant growth factor in a volume of 1 ml. After 15 min air drying, sponge pieces were quickly rolled in Hydron NCC polymer (Hydro Med Sciences, Cranbury, NJ, USA) 12% in PBS 95% ethanol to promote the delayed release of the angiogenic factor, allowed to dry for an additional 30 min, and kept on ice inside a sterile 3-cm Petri dish until implantation.
Implantation of growth factor-loaded sponges into mouse ears
Mice were anesthetized intraperitoneally with 20 ml avertin/g of body weight and their ears cleaned with 2% chlorexidin solution. An incision was performed at the base of the pinna between the skin layers with the tip of an MC40 straight forceps (Moria, Antony, France). One branch of the forceps was used to create a canal progressing over 5 mm between two near-parallel branches of the existing blood vessels, up to the edge of the pinna. An iris forceps (MC 34, Moria) bent at a 451 angle was used to create a 1-2 mm 2 pocket and to insert therein the sponge implant at the end of the canal. The two ear skin sheets were then pressed together below the pocket in order to favor healing. When performed carefully, this procedure did not result in noticeable bleeding. Angiogenesis at the implant site was checked daily. Every 2-3 days, animals were anesthetized and both sides of the ears photographed under transillumination using a Leica MZFLIII stereomicroscope. After killing, ears were resected, fixed in PBS containing 4% paraformaldehyde and processed for paraffin embedding.
TNP-470 inhibition of FGF-2-induced angiogenesis
Animals received ear implants as above, loaded with either 250 ng FGF-2 or solvent alone. A measure at 30 mg/kg TNP-470 (a kind gift of Drs Ikeda and Miyashita, Takeda Chemical Industries, Osaka) in PBS with 5% gum arabic, or solvent alone, was injected subcutaneously in the back every 2 days.
Intravital fluorescence microscopy
Anesthetized animals received injections of 100 ml PBS with 2% FITC-dextran in the tail vein (MW 250 000, Sigma). They were then placed under an epifluorescence confocal microscope (Olympus Fluoview). Serial confocal sections were acquired and compiled to image vascular architecture within 500 mm of the implantation site. Similar protocols were repeated on different animals.
Preparation of concentrated viral stocks
Confluent cultures of MFG-LacZ-or MFG-Ets1-DB-IresNeo R -or MFG-Ires-Neo R -producing GP + E86 cells were incubated overnight in a small volume of serum-free culture medium. Supernatants were collected and centrifuged at 1300 r.p.m. for 15 min at 41C to remove cellular fragments. Supernatants were then centrifuged at 41C for 2.5 h at 23 000 r.p.m. The transparent and viscous pellet was resuspended in 800 ml sterile PBS by repeated pipetting and shaking on ice for at least 1 h.
Titers of retroviral infectious particles (i.p.) were estimated by incubating mouse NIH-3T3 fibroblasts with serial dilutions of the concentrated retroviral pellets for 8 h and performing bgalactosidase staining of infected cells after 2 additional days of culture (for MFG-LacZ supernatants) or counting the number of geneticin-resistant NIH-3T3 clones obtained after 7-10 days (for MFG-Ets1-DB-Ires-Neo R or MFG-Ires-Neo R supernatants).
Administration of retroviral vectors to mice
Concentrated retroviral stocks resuspended in PBS were quickly warmed to room temperature just before injection. Animals implanted with FGF-2-loaded sponges were injected intravenously under anesthesia with 80-100 ml of this suspension containing 1-3 Â 10 7 MFG-LacZ, MFG-Ets1-DB-IresNeo R or control MFG-Ires-Neo R i.p.
Implantation of tumor cells into mice ears
Female nu/nu BALB/c mice, 6 weeks old, were anesthetized and their ears cleaned with 2% chlorexidin solution. Canals were prepared as described for FGF-2-loaded sponge implants but starting from the margin to the base of the ear. This orientation avoids fluid leakage before the tumor starts developing. A sponge implant was inserted using the iris bent forceps and 2 Â 10 5 MFG-Ets1-DB-Ires-Neo R -or MFG-IresNeo R -producing GP + E86 cells in 1 ml PBS was deposited in the pocket using a Hamilton syringe (75 RN gauge 26S taper Y pst 2). The two ear skin sheets at the top of the canal were then pressed together to favor healing. Tumor development was checked daily. At the time of killing, ears were dissected, fixed in PBS with 4% paraformaldehyde and processed for paraffin embedding.
Histological analyses and in situ hybridization
Tissue sections of 7 mm were deparaffinized and processed for histological analysis after staining with hematoxylin/eosin or May-Gru¨nwald-Giemsa dye.
For perfused vessel counts, only vessels lined by endothelial cells, closed and filled with at least four red blood cells, were taken into account. Immunohistodetection of the endothelial marker CD31/PECAM was performed as follows. Deparaffinized tissue sections were incubated for 30 min at room temperature in PBS with 2.5 mg/ml trypsin to restore antigen accessibility. After inhibiting endogenous peroxidases using 1% hydrogen peroxide in PBS, 80% methanol, tissue sections were incubated for 30 min in PBS containing 0.5% casein. Sections were then incubated overnight at 41C with rat antimouse CD31/PECAM antibodies (Pharmingen, 01951A) diluted 1 : 10 in PBS, 0.5% casein. After three washes in PBS, 0.05% Tween 20, tissue sections were incubated for 2.5 h at 41C with biotinylated donkey anti-rat immunoglobulins (Jackson Immunoresearch Labs, ref 65-153) diluted 1/5000 in PBS 0.5% casein. Two washes in PBS, 0.05% Tween 20 were then performed, followed by further washing in PBS prior to incubation for 1 h in avidin-horseradish peroxidase (Vector, A 2004) diluted 1 : 1000 in PBS. DAB chromogen (DAKO) was used as the peroxidase substrate. Chromogenic reaction was visually monitored, and stopped by adding tap water. Tissue sections were counterstained with Mayer hematoxylin.
The presence of MFG-Ets1-DB-Ires-Neo R or MFG-IresNeo R retroviral transcripts was assessed by detecting the neomycin-resistance gene expression. The neomycin-resistance gene was cloned into the Bluescript KS + plasmid vector and transcribed into sense and antisense 35 S-labeled RNA probes for in situ hybridization, which was performed as described previously (Wernert et al., 1994) . Sense probes consistently failed to produce any signal.
